GSA Capital Partners LLP Buys Shares of 77,577 Alphatec Holdings, Inc. (NASDAQ:ATEC)

GSA Capital Partners LLP bought a new position in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 77,577 shares of the medical technology company's stock, valued at approximately $431,000. GSA Capital Partners LLP owned 0.05% of Alphatec as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in ATEC. Point72 Asset Management L.P. grew its holdings in Alphatec by 65.2% in the 2nd quarter. Point72 Asset Management L.P. now owns 3,192,789 shares of the medical technology company's stock worth $33,365,000 after acquiring an additional 1,260,137 shares during the last quarter. Magnetar Financial LLC bought a new stake in shares of Alphatec in the second quarter worth about $10,957,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in Alphatec by 23.8% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,630,244 shares of the medical technology company's stock valued at $27,486,000 after purchasing an additional 505,202 shares during the period. Granite Investment Partners LLC raised its position in Alphatec by 130.2% during the 2nd quarter. Granite Investment Partners LLC now owns 664,201 shares of the medical technology company's stock valued at $6,941,000 after purchasing an additional 375,621 shares during the last quarter. Finally, AlphaCentric Advisors LLC purchased a new stake in Alphatec in the 3rd quarter worth approximately $2,057,000. 66.35% of the stock is currently owned by institutional investors.

Alphatec Trading Up 3.8 %

NASDAQ:ATEC opened at $9.93 on Thursday. The stock has a market cap of $1.41 billion, a price-to-earnings ratio of -7.76 and a beta of 1.31. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The company's 50 day moving average price is $6.52 and its 200-day moving average price is $8.28. Alphatec Holdings, Inc. has a 52 week low of $4.88 and a 52 week high of $17.34.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on ATEC shares. Wells Fargo & Company reduced their target price on Alphatec from $26.00 to $19.00 and set an "overweight" rating on the stock in a research note on Thursday, August 1st. Stifel Nicolaus reduced their price objective on shares of Alphatec from $19.00 to $16.00 and set a "buy" rating on the stock in a research report on Thursday, August 1st. Piper Sandler dropped their target price on shares of Alphatec from $17.00 to $12.00 and set an "overweight" rating for the company in a research report on Thursday, August 1st. HC Wainwright reiterated a "buy" rating and set a $20.00 price target on shares of Alphatec in a research report on Thursday, October 31st. Finally, Barclays raised their target price on Alphatec from $19.00 to $20.00 and gave the company an "overweight" rating in a research note on Tuesday. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $17.11.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.